RESULTS Four RCTs were identified and included in the present study: 19122 patients with AF and HF were allocated to a NOAC (13384 receiving single/high-dose NOAC), and 13390 to warfarin. Single/highdose NOACs significantly reduced the incidence of stroke or systemic embolic events by 14% (Odds Ratio [OR]: 0.86, 95%Confidence interval [CI]: 0.76-0.98). Low-dose NOACs had comparable efficacy to warfarin for the stroke or systemic embolic events (OR 1.02; 95%CI: 0.86-1.21). A 24% reduction in major bleeding was seen with single/ high-dose NOACs, compared with those with warfarin (OR: 0.76, 95% CI: 0.67-0.86). For low-dose NOACs, the OR for major bleeding was 0.64 but without significant difference(95%CI: 0.38-1.07). Among the 42361 patients allocated to a NOAC, the outcomes were compared between AF patients with HF and those without HF. Regardless of high-or low-dose NOAC regimes, the incidences of both major bleeding and the composite of stroke or systemic embolism in AF patients with HF were similar to those without HF. In patients with AF and HF, a 41% reduction in intracranial bleeding was observed (OR: 0.59, 95%CI: 0.40-0.87), perhaps driven by differences in comorbidities between both groups.
OBJECTIVES Recent studies show the existence of autophagy in cerebral ischemia; however, no studies have been found to examine the role of autophagy in cerebral injury after cardiopulmonary resuscitation (CPR). This study was to determine the role of autophagy in rats model of ventricular fibrillation (VF)/CPR. METHODS Experiment 1:48 adult Wistar rats were subjected to VF by an external transthoracic alternating current, left untreated for 6 minutes, and then administered CPR to observe the existence of autophagy after return of spontaneous circulation (ROSC). Experiment 2:72 rats were pretreated with intraperitoneal injections of either saline (Control group), the autophagy inducer rapamycin (Rapamycine group) or the autophagy inhibitor 3-methyladenine (3-MA group) after ROSC at once to evaluate the contribution of autophagy to neuronal injury after ROSC.
RESULTS Our results showed that autophagy activation attenuated 2 to 4 hours after ROSC and was related to the decrease in 5'-AMPactivated protein kinase (AMPK) activity after ROSC. Rapamycine treatment significantly increased the expression of LC3-II and Beclin-1 after ROSC, attenuated the activation of casepase-3, promoted neuron survival and decreased neuron apoptosis, and improved the neurological deficit score after CPR. In contrast, 3-MA pretreatment significantly attenuated the expression of LC3-II and Beclin-1 and worsened the neurological outcome after ROSC.
CONCLUSIONS Autophagy activation after ROSC shows remarkable tolerance to VF/CPR ischemic insults, and improves neurological outcomes.
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Survival from Out-of-hospital Cardiac Arrests without Return of Spontaneous Circulation in the Field Yan Xiong, 1,2 Ngozi Okoro, 1 Denise Mitchell, 1 Megan Dwyer, 1 Auna Leatham, 1 Gilberto Salazar, 1 Ahamed Idris 1 1 University of Texas Southwestern medical center; 2 The First Affiliated Hospital of Sun Yatsen University OBJECTIVES Prompt and proper field resuscitation is vital for survival from out-of-hospital cardiac arrest (OHCA). Return of spontaneous circulation (ROSC) in the field is one of the most important determinants contributing to survival and favorable neurological outcomes following OHCA. However, nearly one third of the survivors in our site were patients without ROSC achieved in the field. In this study we described the demographics, pre-hospital characteristics and outcomes of patients with OHCA in our resuscitation research center, who were treated on scene and transported to hospitals, and compared survivors who did and did not have ROSC in the field, as well as those who met the universal Termination of Resuscitation (TOR, no ROSC, not EMS witnessed, and not shocked)) criteria in the field.
METHODS Resuscitation Outcomes Consortium (ROC), is a clinical research network consisting of eleven regional centers and a data coordinating center in North America that has registry systems and conducts multi-center clinical trials focusing on OHCA and severe trauma. Its goal is to evaluate strategies for pre-hospital treatment of patients with OHCA or life-threatening trauma. Between 2006 throughout April 2011, a total of 10,994 non-traumatic OHCA cases were screened and enrolled in Dallas Fort Worth (DFW) ROC site in Texas. We included cases aged !18years with non-traumatic OHCA treated and transported to a hospital within DFW ROC site. Demographic characteristics, key prehospital factors and resuscitative interventions in the field, for all these treated and transported cases, including survivors with and without ROSC, as well as those who met TOR, were reported.
RESULTS Included were 5,099 OHCA cases; 83.2% (4,243) were patients without ROSC in the field, of which 66.6% (2,827) met TOR criteria in the field but still were treated and transported. Of treated cases, 5.6% (287) survived to hospital discharge; of the 94.4% (4,812) who died, 82.6% (3,975) died in the Emergency Department, while 17.4% (837) died in the hospital. Further analysis of the survivors showed that 72.5% (208) of the survivors had ROSC in the field, and 27.5% (79) did not. Of interest, 10.8% (31) of survivors met TOR criteria, accounting for 1.1% of this special population. EMS immediate resuscitation attempt on witnessed arrest(OR 4.350, 95%CI 1.125-16.819), shock-able initial rhythm (OR 3.053, 95%CI 1.079-8.643), and advanced airway management(OR 0.329, 95%CI 0.104-1.041) were top three significant factors to predict survival of OHCA victims without ROSC in the field. Of concern, 1.7% (47/2827) of victims who met TOR criteria presented initial shock-able rhythm but no shocks were delivered in the field by EMS personnel.
CONCLUSIONS In the DFW ROC site, 27.5% of OHCA survivors were patients without ROSC achieved in the field and 10.8% of the survivors met Termination of Resuscitation criteria in the field. Our data suggest that all treated OHCA patients should be transported to the hospital.
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Salicylic acid renders aspirin resistance via breaking the functional balance of COX-1/COX-2 in diabetic mice OBJECTIVES Aspirin resistance (AR) has become a serious clinical concern. Diabetes is an established risk factor of AR, but the key mechanisms remain elusive. The objective of this study was to uncover whether there was an underlying link between pathogenic accumulation of salicylic acid (SA), the major metabolite of aspirin, and AR in the diabetic state.
METHODS One hundred 8-week-old female C57BL/6 mice were randomly divided into normal control group (n¼20) and high-fat diet and streptozotocin (HFD/STZ) induced diabetic group (n¼80). The diabetic model mice were then randomly divided into four groups and treated respectively with vehicle (0.5% CMC-Na), aspirin (dissolved in 0.5% CMC-Na), equal molar volume of SA (30 mg/kg, i.g) plus aspirin (40 mg/kg, i.g), and aspirin (40 mg/kg, i.g) followed by NaHCO3 (600 mg/kg, i.g). The levels of blood glucose, 24-h urine protein, cholesterol, triglycerides were measured and the pathological changes in the renal tissues were examined by optical microscopy. qRT-PCR analysis was performed to detect the renal organic anion transporters (OATs), sodium-coupled monocarboxylate transporters (SMCTs) and uric acid transporter 1 (URAT1). Platelet function was analyzed using flow cytometric analysis of platelet P-selectin (CD62P). Thromboxane (TX) B 2 and 6-keto-prostaglandin (PG) F 1a contents were determined by radioimmunoassay and the concentration of SA in plasma was measured with high-performance liquid chromatography (HPLC).The OBJECTIVES Both the CHADS 2 and CHA 2 DS 2 -VASc scores are wellvalidated for predicting risk of stroke among patients with atrial fibrillation (AF), but most validation studies have been in Western populations. Some uncertainty is evident for the selection of which score to guide optimal anticoagulant therapy among Asian populations with AF. We aimed to perform a systemic review and meta-analysis of available studies to compare CHADS 2 and CHA 2 DS 2 -VASc scores for risk stratification and second, to establish which score has a better performance in identifying 'truly low risk' AF patients from Asia.
METHODS A systemic literature search of Cochrane library, Scopus, and PubMed databases was conducted using search terms including atrial fibrillation, CHADS 2 and CHA 2 DS 2 -VASc. Stroke / thromboembolism outcome events at low, moderate, and high risk groups were compared in relation to both scores. Statistical analyses were performed using Revman 5.3 software.
RESULTS 493 records were retrieved, of which 6 cohort studies focusing on non-anticoagulated patients from Asian regions were appraised and included. Absolute event rates were usually lower when patients were categorized as CHA 2 DS 2 -VASc of 0-1, rather than CHADS 2 of 0-1, respectively. Meta-analysis revealed that when compared with the CHA 2 DS 2 -VASc score, there was a 1.71-fold (95% confidence intervals (CI): 1.26-2.31) elevated risk of stroke when patients were stratified as 'low risk' using a CHADS 2 score¼0, or a 1.40-fold (95%CI: 1.20-1.64) increase with a CHADS 2 score¼1. A 1.19-fold (95%CI: 1.02-1.38) elevated risk was observed amongst CHADS2 score !2, but the total number of events were higher when patients were categorized as CHA 2 DS 2 -VASc !2.
CONCLUSIONS The CHA 2 DS 2 -VASc score is superior to the CHADS 2 score in identifying 'truly low risk' Asians patients with AF. Rather than a categorical (ie. low/moderate/high risk) approach, Asian guidelines should adopt a 2 step approach, by initially identifying the low risk patients (using the CHA 2 DS 2 -VASc score) who do not need any thromboprophylaxis, following which effective stroke prevention can be offered to those with !1 stroke risk factors.
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Prognostic importance of C-reactive protein in acute myocardial infarction: A systematic review and meta-analysis of prospective studies Jiayu Diao, Jin Wei Department of Cardiology, The Second Affiliated Hospital of Xi'an Jiaotong University OBJECTIVES It was controversial that whether C-reactive protein (CRP) was a prognostic marker in patients with acute myocardial infarction (AMI). We undertook this meta-analysis to make it clear.
METHODS A systematic literature search was conducted using Medline, PubMed, and Web of Science for prospective studies of patients with AMI that reported outcomes according to serum CRP levels. The relationships between levels of CRP and prognoses were assessed.
RESULTS 10368 patients in 9 studies were identified. Long term follow-up varied from 6 months to 10 years. Mean level of CRP was 8.79mg/L. High CRP levels were associated with higher mortality(odds ratio, 2.40; 95% CI, 1.44 to 3.99; P<0.001) and more heart failure (odds ratio, 2.08; 95% CI, 1.49 to 2.89; P<0.001). The risk of mortality remained evident in subgroup analyses according to cut-off level of CRP. For the cut-off level of 3 mg/L and 10mg/L, the odds ratios of mortality were 2.69 (95% CI, 1.06 to 6.82, P ¼ 0.04) and 2.32 (95% CI, 1.18 to 4.55, P¼0.01), respectively.
CONCLUSIONS A high level of serum CRP was significantly associated with poor prognoses in patients with AMI.
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Cystatin C is Associated with Cardiovascular Autonomic Neuropathy in Newly Diagnosed Type 2 Diabetic Patients Xubin Yang, Shangyan Liang, Wen Xu, Yanhua Zhu, Bin Yao, Jianping Weng, Wen Xu Department of Endocrinology and Metabolism, the third Affiliated Hospital of Sun Yat-sen University OBJECTIVES Cardiovascular autonomic neuropathy (CAN) is closely associated with increased mortality in diabetic patients. Several risk factors of CAN have been clearly clarified. However, the impact of cystatin C(Cys C) on CAN is still unclear. Therefore, this study aimed to investigate the association between Cys C and CAN in newly diagnosed type 2 diabetic patients with normal renal function and urinary albumin excretion rate (UAER).
METHODS 90 newly diagnosed type 2 diabetic patients (58% male, mean age: 48 years old) were enrolled. Heart rate variability (HRV) measured by Holter were used to identify CAN. Cys C was measured by particleenhanced turbidimetric immunoassay (PETIA). Based on the results from HRV, subjects were then further divided into two groups: diabetic patients with CAN (CANþ group) or without CAN (CAN-group).
RESULTS
The positive rate of CAN in newly diagnosed type 2 diabetic patients was 35.6%. Compared with CAN-group (n ¼58), CANþ group (n ¼32) had significantly higher Cys C (0.97AE 0.32 vs. 0.75 AE 0.14 mg/L, P ¼0.02) but no significant differences were observed in creatine, glycated hemoglobin (HbA1c) or UAER between groups. Cys C was correlated with SDNNINDEX (r ¼-0.38, P ¼0.04), Low frequency domain(LF) (r ¼-0.48, P ¼0.008) and Highfrequency domain(HF) (r ¼-0.49, P ¼0.006). Logistic regression analysis revealed that Cys C was an independent risk factor of CAN in this population (OR:1.71, 95%CI:1.57w1.87, P ¼0.037) after adjusting for creatine, HbA1c and systolic blood pressure.
CONCLUSIONS Prevalence of cardiovascular autonomic nerve is high in newly diagnosed type 2 diabetic patients with normal renal function and UAER. Cys C is associated with CAN in this population.
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Suboptimal oral anticoagulation use among Chinese nonvalvular Atrial Fibrillation Patients: the Nanchang Atrial Fibrillation project
